Natera Files Additional Suit Against ArcherDX

Rhea-AI Summary

Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, has filed a lawsuit against ArcherDX, Inc. for the infringement of its U.S. Patent No. 10,731,220, issued on August 4, 2020. The lawsuit, filed in the U.S. District Court of Delaware, alleges that ArcherDX's oncology products violate Natera's patented methods related to DNA testing. This follows a prior suit filed against ArcherDX in January 2020 regarding four additional patents. Natera seeks both monetary damages and injunctive relief for these infringements.

Positive

• Natera has over 200 patents in its intellectual property portfolio, strengthening its market position.
• The patent '220 is crucial for Natera's oncology-related products, potentially leading to competitive advantages.

Negative

• Ongoing litigation may divert resources and management focus from business operations.
• Risks associated with patent disputes could impact Natera's market perception and financial stability.

SAN CARLOS, Calif., Aug. 7, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, filed suit yesterday against ArcherDX, Inc. for infringement of Natera's U.S. Patent No. 10,731,220 (the "'220 Patent"). The complaint was filed in the U.S. District Court of Delaware.

The '220 Patent is titled "Methods for Simultaneous Amplification of Target Loci" and was issued by the United States Patent and Trademark Office on August 4, 2020. The '220 Patent is one of more than 200 patents issued or pending in Natera's global intellectual property portfolio, including more than 60 in the field of oncology.

Natera's complaint alleges that ArcherDX's sale and use of certain cell-free DNA-based oncology products infringes on the '220 Patent. In January of 2020, Natera filed suit in Delaware against ArcherDX (C.A. No. 20-125), asserting four additional patents. Natera is seeking injunctive relief and monetary damages in both cases.

About Natera

Natera is a pioneer and global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology, and organ health. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com. Follow Natera on LinkedIn. 

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to developments in matters under dispute or litigation, the scope of protection we establish and maintain for, and developments or disputes concerning, our intellectual property or other proprietary rights, our efforts to develop and commercialize new product offerings, and our ability to successfully increase demand for and grow revenues for our product offerings. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

Contacts
Investor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090
Media: Paul Greenland, VP of Corporate Marketing, Natera, Inc., pr@natera.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/natera-files-additional-suit-against-archerdx-301108279.html

SOURCE Natera, Inc.

FAQ

What is the latest lawsuit filed by Natera against ArcherDX regarding patent infringement?

Natera filed a lawsuit against ArcherDX for infringing its U.S. Patent No. 10,731,220 on August 7, 2020.

What is U.S. Patent No. 10,731,220 related to?

The patent is titled 'Methods for Simultaneous Amplification of Target Loci' and relates to cell-free DNA testing.

What were the details of Natera's previous lawsuit against ArcherDX?

In January 2020, Natera filed a lawsuit asserting four additional patents against ArcherDX in Delaware.

What does Natera seek from its lawsuit against ArcherDX?

Natera is seeking injunctive relief and monetary damages as part of its lawsuit.